Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 15/20 | 0.37 |
| ▸ | KLK1 | P06870 | 5/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.37 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292976 | 0.92 | KDM4C (0.41) | KLKB1KLK1MAP4K1KDM5AKDM2B | |
| SCHEMBL16881351 | 0.89 | KLKB1 (0.36) | KLKB1KLK1MAP4K1KDM5AKDM4C | |
| SCHEMBL21305557 | 0.83 | TYK2 (0.37) | KLKB1KLK1 | |
| SCHEMBL18360306 | 0.82 | KLKB1 (0.56) | KLKB1KLK1MAP4K1 | |
| SCHEMBL20266860 | 0.82 | KLKB1 (0.51) | KLKB1KLK1MAP4K1 | |
| SCHEMBL16880771 | 0.81 | KLKB1 (0.62) | KLKB1KLK1MAP4K1 | |
| SCHEMBL16891551 | 0.81 | KLKB1 (0.57) | KLKB1MAP4K1 | |
| SCHEMBL21305551 | 0.80 | KLKB1 (0.42) | KLKB1KLK1MAP4K1 | |
| SCHEMBL18360084 | 0.80 | KLKB1 (0.45) | KLKB1KLK1MAP4K1 | |
| SCHEMBL20266917 | 0.80 | KLKB1 (0.58) | KLKB1KLK1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981893-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981893-B2 | Therapeutic inhibitory compounds | SERPINB1, KLKB1, SERPINE1 | KLKB1 2/4885KLK1 5/4885MAP4K1 271/4885 |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | SERPINB1, KLKB1, SERPINE1 | KLKB1 2/4885KLK1 6/4885MAP4K1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.